Good Start Genetics to develop pre-pregnancy genetic test with completed $18M Series A financing

Good Start Genetics, Inc., today announced the completion of an $18 million Series A financing. The proceeds of this financing will be used to complete the development and launch of the Company's pre-pregnancy genetic test, which utilizes advanced DNA sequencing technology to screen for a panel of genetic disorders including those recommended by the American Congress of Obstetricians and Gynecologists (ACOG) and the American College of Medical Genetics (ACMG). The financing was led by OrbiMed Advisors, Safeguard Scientifics, Inc. (NYSE: SFE) and SV Life Sciences.

“The diagnostic industry demands tools that provide physicians with highly accurate genetic information that is clinically valuable for individual patients. Under the leadership of Don Hardison, Good Start Genetics has the technology, experience and vision to make this goal a reality.”

The Company also announced that Don Hardison, former COO of LabCorp and CEO of Exact Sciences, has been appointed President, CEO and Director of the Company. Good Start Genetics' Board of Directors is chaired by Marc Beer, former CEO of ViaCell, and also includes Robert Carpenter, Director of the Genzyme Corporation; Carl Gordon, General Partner at OrbiMed Advisors; Gary Kurtzman, Managing Director at Safeguard Scientifics; and Lutz Giebel, Managing Partner at SV Life Sciences.

Good Start Genetics' advanced DNA sequencing technology is designed to deliver a higher detection rate and improved clinical performance compared to currently available screening methods, such as genotyping and SNP analysis. Higher detection rates provide physicians with more accurate results and more clinically relevant genetic information. The Good Start Genetics test will allow physicians to better identify carriers of heritable genetic disorders, enabling physicians to help prospective parents make more knowledgeable medical decisions. The Company expects to launch its test exclusively through board certified physicians in the U.S. starting in 2011.

"We expect this test to be widely adopted as the new clinical standard of care for pre-pregnancy genetic screening," said Marc Beer, Chairman of the Board of Good Start Genetics. "The diagnostic industry demands tools that provide physicians with highly accurate genetic information that is clinically valuable for individual patients. Under the leadership of Don Hardison, Good Start Genetics has the technology, experience and vision to make this goal a reality."

Unlike other companies, which offer their tests online or direct-to-consumers, Good Start Genetics will offer its test exclusively through board certified physicians in a clinical setting. "It is our belief that the only way to make these truly important decisions is under the professional guidance of a physician, who can evaluate genetic information in the context of a patient's comprehensive medical profile," commented Mr. Hardison. "Good Start Genetics is moving beyond the existing one-size-fits-all genetic testing paradigm because we believe that genetic information is a critical and a completely individual aspect of healthcare. Our product will allow physicians to select from a broad panel of disorders, and customize their test order to meet the individual screening needs of each prospective parent."

Don Hardison is a clinical diagnostic industry leader with over 28 years of management and commercial experience. Prior to joining Good Start Genetics, Mr. Hardison was an Executive Vice President and Chief Operating Officer at Laboratory Corporation of America. Previously, Don served as President and Chief Executive Officer at EXACT Sciences, an applied genomics and biotechnology company focused on the early detection of cancer. He has also held leadership roles at SmithKline Beecham Corporation and Quest Diagnostics.

Good Start Genetics received initial seed financing from the Massachusetts Life Sciences Center's Accelerator Program.